Form 4: Aquestive Therapeutics Executive Stephen Wargacki Reports Stock Disposals to Cover Tax Obligations

Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, reports disposing of shares to cover tax obligations related to vesting Restricted Stock Units.

Summary

• Stephen Wargacki, SVP of Research & Development at Aquestive Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 9, 2024, 11,269 common stock shares were disposed of to satisfy tax withholding obligations at a price of $4.88 per share, leaving him with 259,650 shares.
• On March 10, 2024, an additional 1,687 common stock shares were disposed of for the same reason, leaving him with 257,963 shares.
• These disposals were related to the vesting of previously granted Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock disposals for tax purposes, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Disposals to cover tax obligations are common when RSUs vest.

Stakeholder Impact

• The stock disposal may have a minor impact on shareholders due to the increased supply of shares in the market, but it is unlikely to be significant.

Key Dates